The diagnosis, natural history and treatment of amyloidosis: The Goulstonian Lecture 1995

Journal of the Royal College of Physicians of London

Volumn 31, Issue 5, 1997, Pages 552-560

  Hawkins, P N ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; RADIOACTIVE IODINE; SERUM AMYLOID P;

AMYLOIDOSIS; HUMAN; METABOLISM; PATHOPHYSIOLOGY; REVIEW; SCINTISCANNING;

AMYLOIDOSIS; HUMANS; IODINE RADIOISOTOPES; RADIONUCLIDE IMAGING; SERUM AMYLOID P-COMPONENT;

EID: 0031216437     PISSN: 00358819     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Booth DR, Sunde M, Bellotti V, Robinson CV, et al. Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature 1997;385:787-93.
2. Axelrad MA, Kisilevsky R, Willmer J, Chen SJ, Skinner M. Further characterisation of amyloid-enhancing factor. Lab Invest 1982;47:139-46.
3. Ganowiak K, Hultman P, Engstrom U, Gustavsson A, Westermark P. Fibrils from synthetic amyloid-related peptides enhance development of experimental AA amyloidosis in mice. Biochem Biophys Res Commun 1994;199:306-12.
4. Lorenzo A, Razzaboni B, Weir GC, Yankner BA. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 1994;368:756-60.
5. Pepys MB, Dyck RF, de Beer FC, Skinner M, Cohen AS. Binding of serum amyloid P component (SAP) by amyloid fibrils. Clin Exp Immunol 1979;38:284-93.
6. Tennent GA, Lovat LB, Pepys MB. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer's disease and systemic amyloidosis. Proc Natl Acad Sci USA 1995;92:4299-303.
7. Emsley J, White HE, O'Hara BP, Oliva G, et al. Structure of pentameric human serum amyloid P component. Nature 1994;367:338-45.
8. Nelson SR, Tennent GA, Sethi D, Gower PE, et al. Serum amyloid P component in chronic renal failure and dialysis. Clin Chim Acta 1991;200:191-200.
9. Hawkins PN, Wootton R, Pepys MB. Metabolic studies of radioiodinated serum amyloid P component in normal subjects and patients with systemic amyloidosis. J Clin Invest 1990;86:1862-9.
10. Hutchinson WL, Noble GE, Hawkins PN, Pepys MB. The pentraxins, C-reactive protein and serum amyloid P component, are cleared and catabolized by hepatocytes in vivo. J Clin Invest 1994;94:1390-6.
11. Pepys MB, Rademacher TW, Amatayakul-Chantler S, Williams P, et al. Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure. Proc Natl Acad Sci USA 1994;91:5602-6.
12. Hawkins PN, Myers MJ, Lavender JP, Pepys MB. Diagnostic radionuclide imaging of amyloid: biological targeting by circulating human serum amyloid P component. Lancet 1988;i:1413-18.
13. 123I-labeled serum amyloid P component. N Engl J Med 1990;323:508-13.
14. Hawkins PN, Tyrrell P, Jones T, Rossor MN, et al. Metabolic and scintigraphic studies with radiolabeled serum amyloid P component in amyloidosis: applications to cerebral deposits and Alzheimer disease with positron emission tomography. Bull Clin Neurosci 1991;56:178-90.
15. Hawkins PN, Richardson S, MacSweeney JE, King AD, et al. Scintigraphic quantification and serial monitoring of human visceral amyloid deposits provide evidence for turnover and regression. QJM 1993;86:365-74.
16. Hawkins PN, Richardson S, Vigushin DM, David J, et al. Serum amyloid P component scintigraphy and turnover studies for diagnosis and quantitative monitoring of AA amyloidosis in juvenile rheumatoid arthritis. Arthritis Rheum 1993;36:842-51.
17. Hawkins PN, Vigushin DM, Richardson S, Seymour A, Pepys MB. Evaluation of 100 cases of systemic AL amyloidosis by serum amyloid P component (SAP) scintigraphy. In: Kisilevsky R, Benson MD, Frangione B, Gauldie J, et al (eds). Amyloid and amyloidosis 1993. Pearl River, New York: Parthenon Publishing, 1994:209-11.
18. Hawkins PN, Vigushin DM, Richardson S, Seymour A, et al. Natural history and regression of amyloidosis. In: Kisilevsky R, Benson MD, Frangione B, Gauldie J, et al (eds). Amyloid and amyloidosis 1993. Pearl River, New York: Parthenon Publishing, 1994:638-41.
19. Holmgren G, Ericzon B-G, Groth C-G, Steen L, et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 1993;341: 1113-16.
20. Hall R, Hawkins PN. Cardiac transplantation for AL amyloidosis: a personal account. Br Med J 1994;309:1135-7.
21. 123I-serum amyloid P component. Lancet 1991;338:335-9.
22. Tan SY, Irish A, Winearls CG, Brown EA, et al. Long term effect of renal transplantation on dialysis-related amyloid deposits and symptomatology. Kidney Int 1996;50:282-9.
23. Hartmann A, Holdaas H, Fauchald P, Nordal KP, et al. Fifteen years' experience with renal transplantation in systemic amyloidosis. Transplant Int 1992;5:15-18.
24. Greipp PR, Kyle RA, Bowie EJ. Factor X deficiency in primary amyloidosis: resolution after splenectomy. N Engl J Med 1979; 301:1050-1.
25. Schnitzer TJ, Ansell BM. Amyloidosis in juvenile chronic polyarthritis. Arthritis Rheum 1977;20:245-52.
26. Ahlmen M, Ahlmen J, Svalander C, Bucht H. Cytotoxic drug treatment of reactive amyloidosis in rheumatoid arthritis with special reference to renal insufficiency. Clin Rheumatol 1987;6:27-38.
27. Berglund K, Keller C, Thysell H. Alkylating cytostatic treatment in renal amyloidosis secondary to rheumatic disease. Ann Rheum Dis 1987;46:757-62.
28. Wilkins J, Gallimore JR, Tennent GA, Hawkins PN, et al. Rapid automated enzyme immunoassay of serum amyloid A. Clin Chem 1994;40:1284-90.
29. Gertz MA, Kyle RA, Greipp PR. Response rates and survival in primary systemic amyloidosis. Blood 1991;77:257-62.
30. Zingraff J, Drucke T. Can the nephrologist prevent dialysis-related amyloidosis? Am J Kidney Dis 1991;18:1-11.
31. Koch KM. Dialysis-related amyloidosis [clinical conference]. Kidney Int 1992;41:1416-29.
32. 2-microglobulin type: a complication of long term haemodialysis. J Clin Pathol 1987;40:1247-51.
33. Benhamou CL, Bardin T, Noel LH, Cornelis F, et al. Beta-2-microglobulin amyloidosis as a complication of peritoneal dialysis treatment. Clin Nephrol 1988;30:346.
34. 2-microglobulin amyloidosis in chronic renal failure. N Engl J Med 1990;323:1070-1.
35. 2-microglobulin amyloid deposits in a uremic patient before chronic hemodialysis. Nephron 1991;59:654-7.
36. Bardin T. Low-dose prednisone in dialysis-related amyloid arthropathy. Rev Rheum Engl Ed 1994;61 (Suppl):97-100S.
37. Campistol JM, Ponz E, Munoz GJ, Oppenheimer F, et al. Renal transplantation for dialysis amyloidosis. Transplant Proc 1992;24:118-19.
38. Jadoul M, Malghem J, Pirson Y, Maldague B, van Ypersele de Strihou C. Effect of renal transplantation on the radiological signs of dialysis amyloid osteoarthropathy. Clin Nephrol 1989;32:194-7.
39. 30). Clin Genet 1991;40:242-6.
40. Skinner M, Lewis WD, Jones LA, Kasirsky J, et al. Liver transplantation as a treatment for familial amyloidotic polyneuropathy. Ann Intern Med 1994;120:133-4.
41. Parrilla P, Lopez-Andreu FR, Ramirez P, Bueno FS, et al. Familial amyloidotic polyneuropathy type I (Andrade's disease): A new indication for liver transplant. Transplantation 1994;57:473-5.
42. Steen L, Holmgren G, Suhr O, Wikström L, et al. World-wide survey of liver transplantation in patients with familial amyloidotic polyneuropathy. Amyloid: Int J Exp Clin Invest 1994;1:138-42.
43. Vidal R, Garzuly F, Budka H, Lalowsk M, et al. Meningocerebrovascular amyloidosis associated with a novel transthyretin mis-sense mutation at codon 18 (TTRD18G). Am J Pathol 1996;148:361-6.
44. Hardy J. Framing β-amyloid. Nat Genet 1992;1:233-4.
45. Gajdusek DC. Transmissible and non-transmissible amyloidoses: autocatalytic post-translational conversion of host precursor proteins to β-pleated sheet configurations. J Neuroimmunol 1988;20:95-110.